Clinical Trials Browser

Phase 2/3 × Nivolumab × 90 days × Clear all

NCT04929041 2026-03-18

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative

Phase 2/3 Suspended

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05987241 2026-03-18

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Phase 2/3 Recruiting

Muscle Invasive Bladder Urothelial Carcinoma

NCT02339571 2026-03-17

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

Phase 2/3 Active not recruiting

Melanoma

NCT06203600 2026-03-17

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Phase 2/3 Recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus

NCT04396860 2026-03-05

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

Phase 2/3 Completed

159 enrolled 17 charts

Gliosarcoma

NCT07221149 2026-03-04

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

Phase 2/3 Recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT06581406 2026-02-18

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Phase 2/3 Recruiting

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT07392892 2026-02-06

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

Phase 2/3 Not yet recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms